Can CAR-T cell therapy tackle solid tumors too?

| | April 11, 2019
Image: Sam Ogden.
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Last summer, [Cecelia] Barron’s cancer went from stage 2 to stage 3 oligodendroglioma. Behnam Badie, her surgeon at City of Hope, told her that she qualified for an experimental treatment in which her own T cells would be engineered to recognize an antigen on the surface of her tumor cells, then would be injected into her brain.

Five months after the CAR T treatment in September 2018, Barron is feeling well, and her MRIs and PET scans show no signs of Junior’s return. Positive signs like these have Badie and others optimistic that CAR T technology will be effective at killing solid tumors, as it has been for certain liquid cancers. There are a now a number of clinical trials in early stages pursuing the therapy for pancreatic cancer, mesothelioma, lung cancer, breast cancer, and others.

Related article:  Urbanization is a ‘massive unplanned experiment’: How cities affect evolution

Now that a number of clinical trials have demonstrated that CAR Ts can be safely given to patients with solid tumors, just about all investigators working on these immunotherapies for solid tumors are moving toward multiple agents as a next step, whether that’s drug combos, CAR Ts that secrete immune-boosting agents, or T cells engineered to carry more than one type of CAR.

Read full, original post: The Next Frontier of CAR T-Cell Therapy: Solid Tumors

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend